Nilogrin (Nicergoline)

Nicergoline works by blocking alpha‑adrenergic receptors, causing dilation of cerebral blood vessels, and by inhibiting platelet aggregation. These actions increase oxygen and nutrient delivery to the brain, thereby enhancing cerebral perfusion and supporting neurological function.

The prescribed dose of Nilogrin is determined by the treating physician based on the patient’s clinical condition, age, and response to therapy. Dosage may vary, and the prescriber will provide specific instructions tailored to each individual.

Safety data for nicergoline in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Nilogrin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other vasodilators such as pentoxifylline, nicergoline uniquely combines alpha‑adrenergic antagonism with antiplatelet activity, offering both vascular dilation and reduced platelet aggregation. This dual mechanism can provide broader support for cerebral perfusion, though individual response varies and should be evaluated by a clinician.

Nilogrin should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture. Keep the product away from direct sunlight and out of reach of children to maintain its stability and potency.

Nilogrin is taken orally, usually with a glass of water. It can be taken with or without food, but following the prescribing physician’s instructions regarding timing and any dietary considerations is important.

Serious risks include severe hypotension, hepatic dysfunction, significant bleeding due to platelet inhibition, allergic reactions such as rash or anaphylaxis, and rare cases of cardiac arrhythmia or vasospasm. Patients should seek immediate medical attention if any of these symptoms occur.

Nilogrin is contraindicated in patients with known hypersensitivity to nicergoline or other ergot derivatives, those with uncontrolled hypertension, active bleeding disorders, severe liver disease, or who are currently taking other ergot‑based medications. A healthcare professional should evaluate suitability before initiating therapy.